TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4888876
Drug: Propranolol 30
Normalized name: HCTZ 25/PROPRANOLOL 30MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 30 mg twice daily
Study: 25427171
Drug: Topiramate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (300 mg/d)
Study: 25427171
Drug: Levetiracetam (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (2000 mg/d)
Study: 21666939
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 300 mg daily
Study: 19948518
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg at induction of anesthesia and 0.5 mg/kg 8 hours later)
Study: 9145958
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid peels (68% maximum concentration) in addition to 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night.
Study: 9145958
Drug: 2% hydroquinone/10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night (control group).
Study: 3144300
Drug: Chlormethiazole 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole 250 mg
Study: 3144300
Drug: Chlormethiazole 500
Normalized name: chlormethiazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole 500 mg
Study: 25604900
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day DHEA
Study: 24326568
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% solution, applied once daily to the upper eyelid margin for 6 months
Study: 24326568
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% solution
Study: 18077316
Drug: All hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All hormonal treatments (E(2), E(2) + MPA, Tibolone)
Study: 16518347
Drug: BNP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP with ET-B receptor antagonist BQ-788 (50 nmol/min)
Study: 16518347
Drug: BQ-788 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BQ-788 infusion
Study: 3324800
Drug: Naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone treatment
Study: 24281361
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) plus Treatment as Usual (TAU)
Study: 18251623
Drug: Ziprasidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (mean daily dose 84.1 mg/day, SD = 54.8; range, 40-200)
Study: 16825332
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (100 mg for women; 200 mg for men)
Study: 14657829
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron
Study: 14657829
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (3 months)
Study: 11016326
Drug: Additional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional heparin
Study: 9001875
Drug: Cefonicid 1
Normalized name: cefonicid 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid 1 g given by intravenous infusion 30 minutes before the operation
Study: 30231106
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 266 mg
Study: 24886402
Drug: Day Hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day Hospital Mentalization-Based Treatment (MBT-DH)
Study: 15911727
Drug: Treatment costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment costs of $37
Study: 15911727
Drug: Treatment costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment costs of $68
Study: 15911727
Drug: Treatment costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment costs of $162
Study: 15911727
Drug: Treatment costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment costs of $589
Study: 10697395
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (streptokinase or tissue-type plasminogen activator)
Study: 6110093
Drug: LM24056 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM24056 at 100 mg
Study: 6110093
Drug: LM24056 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM24056 at 200 mg
Study: 6110093
Drug: LM24056 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM24056 at 300 mg
Study: 31984963
Drug: Artmaking with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artmaking with fluid materials (e.g., finger paints)
Study: 31984963
Drug: Artmaking with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artmaking with less fluid materials (e.g., gouache paint with a brush)
Study: 25213048
Drug: Fluticasone furoate-vilanterol
Normalized name: Fluticasone Furoate-Vilanterol Ellipta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate-vilanterol 100-25 mcg
Study: 25213048
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 mcg
Study: 21918905
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg per day
Study: 18156033
Drug: Budesonide plus
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide plus formoterol maintenance and reliever therapy
Study: 18156033
Drug: Fixed-dose budesonide
Normalized name: budesonide Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose budesonide plus formoterol
Study: 18156033
Drug: Fixed-dose fluticasone
Normalized name: fluticasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose fluticasone plus salmeterol
Study: 2744909
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) 400 mg/day for 13 days
Study: 2744909
Drug: Phenytoin 300
Normalized name: phenytoin 300 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 300 mg/day for 13 days
Study: 105970
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (200 mg qds)
Study: 8030597
Drug: Taurine 10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine 10.8 mg/kg ideal body weight (group 2)
Study: 8030597
Drug: Taurine 50
Normalized name: taurine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine 50 mg/kg ideal body weight (group 3)
Study: 2729161
Drug: PPBG less
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPBG less than 13 mmol/L
Study: 2729161
Drug: PPBG greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPBG greater than 13 mmol/L
Study: 2729161
Drug: Exclusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusion of participants with PPBG greater than 13 mmol/L
Study: 23698160
Drug: Folate enriched
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate enriched diet (200 μg)
Study: 23698160
Drug: 5-MTHF (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-MTHF (200 μg)
Study: 23698160
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (200 μg)
Study: 20647200
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg twice daily for 52 weeks
Study: 12517200
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of reliever medications
Study: 12517200
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of controller medications
Study: 7137522
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 100 mg sustained-release preparation
Study: 7137522
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 50 mg combined with antihistamine
Study: 7137522
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) 5 mg
Study: 7137522
Drug: PPA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA (100 mg) and combined preparation containing PPA (50 mg) taken twice a day
Study: 30527555
Drug: Guardix® (liquid-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guardix® (liquid-based hyaluronic acid and carboxymethyl cellulose solution)
Study: 16269298
Drug: Bariatric operation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bariatric operation (not specified dosage or duration)
Study: 12162474
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg x 3, q4-6h)
Study: 1972947
Drug: 2% calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% calcium mupirocin ointment after tincture of iodine
Study: 7439516
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose combination of slow-release aminophylline and salbutamol
Study: 29798201
Drug: Binglianqingye Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binglianqingye Spray
Study: 29798201
Drug: Jinsangzi Tablet
Normalized name: BENZALKONIUM CHLORIDE 0.25 g in 100 mL TOPICAL LIQUID [Jinlingzi disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinsangzi Tablet
Study: 29798201
Drug: Jinhoujian Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinhoujian Spray
Study: 27108410
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review (PMC) at study start (T-0) and after 28 weeks (T-28)
Study: 27108410
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review (PMC)
Study: 18421919
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy (WBCT) for 120-180 seconds at temperatures between -110°C and -160°C, 15 treatments over 3 weeks.
Study: 18421919
Drug: Standard psychopharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychopharmacological treatment (not specified)
Study: 15206496
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (10 mg/day enalapril and 50 mg/day losartan)
Study: 15206496
Drug: Double-dose monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose monotherapy (20 mg/day enalapril or 100 mg/day losartan)
Study: 15206496
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (enalapril and losartan)
Study: 1102260
Drug: Methocarbamol (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methocarbamol (1500 mg. q.d.s.)
Study: 31545799
Drug: Diazoxide Choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide Choline Controlled-Release Tablets (DCCR)
Study: 19964499
Drug: Therapist-mediated post-stroke
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-mediated post-stroke rehabilitation using haptic/graphic error augmentation
Study: 16505324
Drug: LY450139 dihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 dihydrate 30 mg for 1 week followed by 40 mg for 5 weeks
Study: 2006723
Drug: Bupivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (20 ml 0.25% every 4 h)
Study: 7096279
Drug: Doxepin HCl
Normalized name: doxepin HCl
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin HCl (50 mg h.s.)
Study: 7096279
Drug: Cimetidine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1000 mg/day in divided doses)
Study: 27007793
Drug: Low-dose spironolactone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spironolactone (25 mg daily)
Study: 31071047
Drug: 3D-DHD (three-dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-DHD (three-dimensional printed dynamic hand device) used twice a week for four weeks, followed by a two-week home program
Study: 19417110
Drug: Valsartan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (mean dose 114 +/- 41 mg/day)
Study: 15336471
Drug: Cizolirtine citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cizolirtine citrate 350 mg IV
Study: 15336471
Drug: Metamizol sodium
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol sodium 2,500 mg IV
Study: 9730125
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin 40 mg daily) for 7 days
Study: 22858264
Drug: DBT-based psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBT-based psychoeducational group (BDG) intervention consisting of 12 weekly 90-min sessions teaching DBT skills, mindfulness techniques, and general BD psychoeducation.
Study: 21163686
Drug: Visible-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visible-light therapy (VLT) device
Study: 17199681
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (compression alone)
Study: 9179456
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.05 mg/day x 21 days) and oral progestogens (10 mg/day medroxyprogesterone acetate [MPA] in the last 12 days, 10 mg/day dihydrogesterone in the last 12 days, and 50 mg/day cyproterone in the first 10 days)
Study: 3531033
Drug: Captopril (Aceten)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (Aceten) 150 mg/day
Study: 3531033
Drug: M-dopa 750
Normalized name: (-)-dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-dopa 750 mg/day
Study: 30282510
Drug: Nexodyn solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexodyn solution on top of standard of care
Study: 28035345
Drug: High-flavonoid fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavonoid fruit and vegetables (>15 mg/100 g)
Study: 28035345
Drug: Low-flavonoid fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavonoid fruit and vegetables (<5 mg/100 g)
Study: 28035345
Drug: High-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol cocoa drink (494 mg total flavanols)
Study: 28035345
Drug: Low-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol cocoa drink (23 mg total flavanols)
Study: 22892813
Drug: High flavanols
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanols (≈990 mg per day)
Study: 22892813
Drug: Intermediate flavanols
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate flavanols (≈520 mg per day)
Study: 22892813
Drug: Low flavanols
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavanols (≈45 mg per day)
Study: 20635829
Drug: Generic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic medication voucher program providing a 30-day supply of 8 specific medications in addition to academic detailing.
Study: 20635829
Drug: Generic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic medication voucher program.
Study: 12629093
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg DHEA (n = 19)
Study: 12629093
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg DHEA
Study: 10475655
Drug: Methylprednisolone 250
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 250 mg at induction of anaesthesia, with a further three doses at 6-hourly intervals postoperatively
Study: 1751266
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and midazolam combination
Study: 1751266
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol and midazolam
Study: 7103030
Drug: Fentanyl with
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl with various anaesthetic agents
Study: 27630318
Drug: Capecitabine (CCB)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (CCB) alone (1,000 mg/m2 bid p.o.)
Study: 27630318
Drug: Capecitabine (CCB)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (CCB) plus Cetuximab (CTX) (loading dose 400 mg/m2 followed by 250 mg/m2 weekly i.v. maintenance dose)
Study: 25158772
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with clopidogrel and aspirin
Study: 21839429
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 40 mg triamcinolone, 2 ml bupivicaine, and 6 ml sterile water for injection
Study: 21839429
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 40 mg triamcinolone and 2 ml bupivicaine
Study: 20421430
Drug: 1.5% dextrose
Normalized name: Delflex with 1.5% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% dextrose solution
Study: 15807814
Drug: Pointed microneedle
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pointed microneedle injections
Study: 15807814
Drug: Symmetric microneedle
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symmetric microneedle injections
Study: 15807814
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application (TA)
Study: 10850522
Drug: Intravenous gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gatifloxacin 400 mg
Study: 10850522
Drug: Oral gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gatifloxacin 400 mg
Study: 8790227
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone at a dose of 0.025 mg/kg body weight/day administered by daily subcutaneous injection over a 6-month study period
Study: 8790227
Drug: Estrogen (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (not specified dosage or duration)
Study: 1637766
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic (2% lignocaine and 0.03 iu/ml octopressin)
Study: 6398314
Drug: Thymopentin 50
Normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin 50 mg, i.v., 3 times a week for 3 consecutive weeks
Study: 22079469
Drug: Oral beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beclomethasone dipropionate (BDP) administered as 1-mg immediate-release formulation plus 1-mg delayed-release formulation orally four times daily.
Study: 22079469
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as per the study design.
Study: 22079469
Drug: Overall adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall adherence to the study drug during the first 4 weeks after hematopoietic cell transplantation.
Study: 22079469
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to the study drug schedule.
Study: 19153943
Drug: drug-free
Normalized name: HEAD CARE Proactive Health Drug-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug-free
Study: 10961470
Drug: Urodynamic examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urodynamic examination before and after delayed treatment starting 6 months after inclusion in the study (Control group)
Study: 3158563
Drug: Fominoben (PB89)
Normalized name: fominoben
DrugBank: Fominoben (DB08968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fominoben (PB89) - 160 mg, 3 times a day for 2 weeks
Study: 3158563
Drug: Dextromethorphan -
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan - 30 mg, 3 times a day for 2 weeks
Study: 29398337
Drug: 80 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g/d prunes (plus 300 ml/d water)
Study: 29398337
Drug: 120 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g/d prunes (plus 300 ml/d water)
Study: 29398337
Drug: Control (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (300 ml/d water)
Study: 29398337
Drug: 80 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g/d prunes
Study: 29398337
Drug: 120 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g/d prunes
Study: 29504445
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression therapy in addition to conventional postoperative rehabilitation
Study: 29504445
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative rehabilitation without intermittent pneumatic compression therapy